To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.
This is the view of Daniel Lim, senior associate at Allen & Overy, who spoke at the Life Sciences Patent Network North America, hosted by LSIPR in Boston.
Lim stated that all the patents that have currently been granted in relation to CRISPR are “foundational patents”.
“What emerged from the panel discussion was the general consensus that these patents, although important especially for freedom to operate and perhaps as a royalty stream for patentees, aren’t really going to be the ones at the pointy end of enforcement,” said Lim.
To find out more, you can watch the video below.
CRISPR, Daniel Lim, Allen & Overy, Life Sciences Patent Network North America, patents, genetics